Insights about drug interactions used in lymphoma treatments and in experimental COVID-19 therapy

• Autor(a) principal: Araújo , Maria Isabela Ferreira de
• Data de Publicação: 2021
• Outros Autores: Silva , Raquel Bezerra da, Barbosa, Paula Perazzo de Souza
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Research, Society and Development
• Texto Completo: https://rsdjournal.org/index.php/rsd/article/view/17962
• topic: SARS-CoV-2; Hodgkin; no Hodgkin; Interacción fármaco-fármaco; Sistema enzimático del citocromo P450.; SARS-CoV-2; Hodgkin; não-Hodgkin; Interação droga-droga; Sistema enzimático do citocromo P450.; SARS-CoV-2; Hodgkin; non-Hodgkin; Drug-drug interaction; Cytochrome P450 enzyme system.

Lymphomas are neoplasms characterized by an immunocompromised tumor environment that induces inflammatory processes whose defense cells production can be further affected by chemotherapy. These details lead to the supposition that individuals with these cancers have more severe clinical complications when contaminated by SARS-CoV-2, which makes it necessary to pay attention to the correct therapeutic management. This study summarizes the drugs used in the treatment of lymphomas and in the experimental therapy of COVID-19, and discusses the possible interactions expected between the drugs used in both illnesses. Most drug-drug interaction occur through changes in the cytochrome P450 enzyme system metabolism or the P glycoprotein efflux transporter (gp-P). Depending of combinations, there may be an increase or decrease in the concentration of the drug and, consequently, an increase in toxicity or a decrease in efficacy, which means that pharmacokinetics should be strongly considered to promote drug safety and better management patients with COVID-19 and lymphomas.